Plasma in Outpatients (C3PO) trial, it was stopped in February 2021 due to lack of efficacy based on a planned interim analysis.
The formal conclusions from the trial appeared in the current online issue of The New England Journal of Medicine. “We were hoping that the use of covid-19 convalescent plasma would achieve at least a 10% reduction in disease progression in this group, but instead the reduction we observed was less than 2%," said Clifton Callaway, the contact principal investigator for the C3PO trial and professor of emergency medicine at the University of Pittsburgh. “That was surprising to us.
As physicians, we wanted this to make a big difference in reducing severe illness and it did not," Callaway said. The Indian Council of